drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting carcinoembryonic antigen (CEA) for MHC-independent recognition and killing of CEA-positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Intraperitoneal
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor with an anti-CEA scFv, enabling MHC-independent recognition of CEA-positive tumor cells and inducing T-cell activation, expansion, cytokine release, and cytotoxic killing via perforin/granzyme pathways.
drug_name
CEA-targeted CAR-T cells
nct_id_drug_ref
NCT06006390